It is possible that the biological and clinical effect of anti-ERBB2 therapy in ovarian carcinoma cases with weak or higher ERBB2 expression will become apparent, if this is evaluated with respect to TP53 status. The gene discussed is TP53; the disease is ovarian carcinoma.